ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

PHVS Pharvaris NV

25.00
-0.42 (-1.65%)
Dec 08 2023 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 243,885
Bid Price 25.42
Ask Price 26.00
News (2)
Day High 25.9875

Low
3.85

52 Week Range

High
29.80

Day Low 24.49
Company Name Stock Ticker Symbol Market Type
Pharvaris NV PHVS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.42 -1.65% 25.00 17:00:00
Open Price Low Price High Price Close Price Prev Close
25.42 24.49 25.9875 25.00 25.42
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,888 243,885 $ 25.44 $ 6,204,767 - 3.85 - 29.80
Last Trade Time Type Quantity Stock Price Currency
18:51:59 1 $ 25.46 USD

Pharvaris NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.02B 40.82M - 0 -76.33M -1.87 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Pharvaris NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No PHVS Message Board. Create One! See More Posts on PHVS Message Board See More Message Board Posts

Historical PHVS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week17.3629.8016.8124.61572,9077.6444.01%
1 Month16.5929.8015.0022.16208,7778.4150.69%
3 Months20.5629.8015.0021.5086,6804.4421.6%
6 Months8.2629.808.2519.2876,54516.74202.66%
1 Year4.1929.803.8511.37491,49520.81496.66%
3 Years25.0042.861.7712.47196,3390.000.0%
5 Years25.0042.861.7712.47196,3390.000.0%

Pharvaris NV Description

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com